Board-level oversight of artificial intelligence has transitioned from a forward-thinking best practice to an emerging governance expectation. Healthcare organization boards must adapt their oversight frameworks to address AI-specific risks and opportunities.

Regulatory signals are clear. The SEC has increased focus on AI-related disclosures. State attorneys general are investigating algorithmic bias. Healthcare-specific regulators are developing AI guidance that implies board accountability. These developments create both legal exposure and fiduciary obligations.

Effective board oversight does not require technical AI expertise among directors. Rather, boards should ensure they receive appropriate information about AI risks, have established clear accountability structures, and can exercise informed judgment about AI governance matters.

Key elements of board AI oversight include regular reporting on AI deployments and associated risks, clear escalation pathways for AI-related incidents, integration of AI considerations into enterprise risk management, and oversight of management’s AI governance capabilities.

Boards should consider whether existing committee structures adequately address AI oversight. Some organizations assign AI governance to audit committees, while others create dedicated technology or innovation committees. The appropriate structure depends on organizational context and the extent of AI deployment.

Management should provide boards with AI risk dashboards that translate technical complexities into governance-relevant metrics. These dashboards should address deployment status, risk classifications, incident trends, and compliance posture against relevant frameworks.

Director education on AI fundamentals helps boards exercise effective oversight. This education should focus on governance implications rather than technical details, enabling directors to ask informed questions and evaluate management’s AI governance approach.